DailyIQ
|
Sector:HealthcareAll sectors
Last updated 6 minutes ago

PODD·Insulet Corporation

$.
-. (-.%)
High
$159.51
Open
$158.01
Market Cap
11.29B
52W High
$354.88
Low
$153.84
P. Close
$162.06
P/E
37.29
52W Low
$138.79
Fwd P/E
20.09
DailyIQ Est.
$257.27
Technical Score (1D)
59
BUY
News Sentiment
64
BULLISH
PODD shares slipped in the last trading session, mirroring a broader medtech selloff triggered by weaker‑than‑expected earnings guidance and a market pivot toward higher‑beta AI infrastructure names. The downgrade in guidance signals that revenue growth may slow, which could dampen investor enthusiasm for the company over the next few days as traders reassess its near‑term outlook. The shift toward AI stocks also suggests that capital is flowing away from traditional medical technology, potentially tightening liquidity for PODD and its peers. ClearBridge’s Q2 2026 SMID Cap Growth Strategy noted PODD’s inclusion but flagged its underperformance relative to the Russell 2500 Growth Index, underscoring that the stock is lagging the broader growth theme. RBC and Truist have both trimmed their price targets to $245 and $210 respectively, while keeping Outperform and Buy ratings, indicating that analysts are tightening valuation expectations amid market volatility. These target cuts may prompt short‑term traders to reprice the stock, creating volatility in the next 1–10 trading days as the market digests the new valuation levels. The company’s upcoming earnings release is the most critical watch item, as any revision to guidance or commentary on its Omnipod platform will either confirm or further erode confidence. Additionally, monitoring the broader medtech sector’s performance will help gauge whether PODD’s decline is idiosyncratic or part of a systemic trend. Finally, keep an eye on any strategic moves by PODD to diversify its revenue streams or invest in AI‑driven solutions, as such initiatives could alter the company’s risk profile and attract new investors.
Earnings Summary
Insulet Corporation is a medical‑device company focused on insulin delivery, offering the Omnipod 5 automated system and the Omnipod DASH platform, and supplying pods for Amgen’s Neulasta Onpro kit. In the medical‑devices sector, Insulet has consistently outperformed peers by expanding its product portfolio and securing regulatory approvals across markets. The company’s recent quarterly results show a strong EPS trajectory: Q4 2024 EPS of $1.15 beat the $1.02102 estimate, Q1 2025 EPS of $1.02 beat $0.78642, Q2 2025 EPS of $1.17 beat $0.92264, Q3 2025 EPS of $1.24 beat $1.14745, Q4 2025 EPS of $1.55 beat $1.17827, and Q1 2026 EPS of $1.42 beat $1.1907, marking six consecutive beats. Revenue, however, has slowed after Q4 2025: it fell from $597.5 million in Q4 2024 to $569 million in Q1 2025, then rose to $649.1 million in Q2 2025, $706.3 million in Q3 2025, $783.8 million in Q4 2025, and dipped to $761.7 million in Q1 2026, reflecting a deceleration in growth. Historically, Insulet has maintained a streak of EPS beats while revenue growth has moderated, indicating a shift toward higher margins. Recent analyst coverage highlights Deutsche Bank’s new Buy rating and $190 target, underscoring confidence in the company’s leadership in the tubeless insulin‑pump market; the coverage follows the firm’s latest quarterly results that beat expectations. Additionally, the launch of Omnipod 5 and the Discover data platform in Spain expands the company’s European footprint and could drive future revenue. Going forward, investors should watch for the Q2 2026 earnings release, guidance on revenue and margin expansion, regulatory approvals in new markets, and competitive pressure from GLP‑1 drugs and pharmacy‑channel rivals, as these factors will shape the company’s near‑term performance.

EPS

EstBeatMiss
$0.67$0.92$1.17$1.42$1.66Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.45 - -
Q1'26$1.19$1.42+19.3%
Q4'25$1.18$1.55+31.5%
Q3'25$1.15$1.24+8.1%
Q2'25$0.92$1.17+26.8%
Q1'25$0.79$1.02+29.7%

Revenue

EstBeatMiss
$534M$610M$686M$762M$838MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$803M - -
Q1'26$730M$762M+4.3%
Q4'25$714M$784M+9.7%
Q3'25 - $706M -
Q2'25 - $649M -
Q1'25 - $569M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

PODD Stock Snapshot

PODD is currently trading at $158.90, giving Insulet Corporation a market cap of 11.29B and a P/E ratio of 37.3. Today's range spans $153.84–$159.51, with shares opening at $158.01 and moving down $3.16 (1.9%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 64/100.

Over the past year PODD has traded between $138.79 and $354.88 - the current price is +14.5% off the 52-week low and -55.2% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $236.83 (range $172.00–$360.00), implying upside of +49.0%.

PODD trades at $158.90 (near 52-week lows within $138.79–$354.88) - and the HOLD signal (59/100) reflects a market that's fairly priced relative to near-term expectations rather than one that's mispriced in either direction. (P/E: 37.3) At 11.29B in Healthcare market cap, bullish sentiment (64/100) confirms the lack of near-term narrative catalyst. The thesis is intact; the timing is patient.

The 52-week range of $138.79–$354.88 for PODD provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $158.90 (near 52-week lows), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 59/100 and bullish news backdrop (64/100) don't break the tie yet, but they narrow the probability distribution toward the upside.